Open Menu
Meetings & Education
Meetings & Education
Research & Data
Practice & Patients
Career Development
News & Initiatives
Get Involved
Phase I/IIa dose finding study of triplet regimen of relatlimab (RELA), ipilimumab (IPI), and nivolumab (NIVO) in first-line therapy of metastatic melanoma (TRINITY).
Background: NIVO (anti-PD1) alone or in combination with IPI (anti-CTLA-4) or RELA (anti-LAG3) are approved immune checkpoint blockade (ICB) agents for the treatment (tx) of patients (pts) with advanced, unresectable metastatic melanoma. Doublet combinations induce higher rates of durable disease control vs single agent, translating into nominal improvements in survival. While there is no established dose-response relationship for NIVO alone or with RELA, IPI at higher doses induces higher objective response rate (ORR) but increased grade ≥3 immune-related adverse events. Deeper mechanistic understanding points towards potential synergy given IPI’s role in expanding the TCR repertoire and modulating suppressive T cell populations while NIVO+RELA regulate the exhaustion signatures of activated T cells and allow for improved effector function. Recently, results from RELATIVITY-048 combining all three ICB agents (NIVO 480 mg Q4W + RELA 160 mg Q4W + IPI 1 mg/kg Q8W) demonstrated impressive efficacy with high response rates (59% ORR) and seemingly improved progression free and overall survival (PFS, OS) over previously reported doublet regimens. This study evaluated a markedly lower IPI dose than the approved regimen and did not include a dose escalation component to optimize the IPI dosing strategy. Our team seeks to optimize the dose and schedule of IPI to combine with NIVO+RELA in order to determine the recommended phase II dose (RP2D) for triplet ICB and maximize clinical benefit while maintaining a toxicity profile comparable to approved regimens.
Methods: In this single center, investigator initiated, phase I/IIa study evaluating triplet ICB (NCT06683755), all pts will receive FDA approved regimen of NIVO 480mg + RELA 160mg IV Q4W along with escalating doses of IPI . Dose escalation (DE) with IPI will begin at 0.5mg/kg Q4W 4 induction doses and will incrementally escalate up to 2mg/kg Q4W. Maintenance tx will consist of NIVO+RELA Q4W. Bayesian optimal interval (BOIN) design will be used to identify the maximum tolerated dose (MTD) and RP2D (primary objective) in the DE portion, accruing an estimated 12-18 pts. The PhIIa portion will accrue an additional 12-18 pts at the RP2D to better characterize safety, and determine the ORR, (primary objective) by RECIST 1.1. Secondary objectives include PFS, OS, and tumor and immunological correlatives obtained on pre and post tx blood and tumor samples. Pts must be previously untreated, unresectable, or advanced melanoma. Non IPI containing prior adjuvant or neo-adjuvant tx will be permitted if the last dose has been >6 months. Pts with asymptomatic brain metastasis are allowed, provided no immunesuppressive doses of corticosteroids are required. Safely biopsiable lesions are required for pts enrolled in the PhII portion. This study is open for accrual at MD Anderson Cancer Center in Houston, Texas.
Disclaimer
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Author Details
Elizabeth Burton
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Authors chevron_right
Associated Organizations chevron_right
Abstract Details
Meeting
2025 ASCO Annual Meeting
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
View MoreAbstract Disclosure
open_in_new
Your Privacy
ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us.
Because we respect your right to privacy, you can choose not to allow some or all types of cookies. Click on the different category headings to find out more about the types of cookies used on our websites and change your default settings to match your preferences. Please read these carefully. Blocking some types of cookies may impact your experience on the site, including our ability to personalize the content you receive from us.
For a full explanation of the personal and non-personal information we collect on our site, including how we use that information and your rights regarding that information, please review our Privacy Policy. Use of our website is also subject to our Terms of Use.
Allow All
Manage Consent Preferences
Essential Website Cookies
Always Active
These cookies are necessary for the website to function and are sometimes referred to as “strictly necessary” cookies. They make sure the website delivers you information and services in an optimal way.
They are often set in response to an action you take, such as changing your cookie preferences, setting your privacy preferences, logging in to our website, asking the site to remember you on subsequent pages, or filling in forms. These cookies do not identify you personally.
You can set your browser to block or alert you about all cookies, including essential website cookies, but some parts of the site will not work as a result.
Cookies Details‎
Performance and Functionality Cookies
Performance and Functionality Cookies
These cookies enhance the performance and functionality of our websites and the services we provide. For example, these cookies can keep track of your visitor session in between visits, enable you to share content through social media, use embedded media players, and use comment features. They also help us balance website load and improve site speed and performance.
All information these cookies collect is aggregated and therefore anonymous. These cookies may be set by us or by third party providers whose services we have added to our websites. These cookies are non-essential, but without these cookies, certain functionality or enhanced features may become unavailable.
Cookies Details‎
Personalization and Analytics Cookies
Personalization and Analytics Cookies
These cookies collect information that is used to help us understand how our websites and content are used, help us customize our websites and application for you in order to enhance your experience, and help us improve the content that ASCO creates to better meet our members’ and visitors’ needs. Examples include cookies that show us which content might be most popular with our visitors, understand browsing history of our users, understand the effectiveness of our own advertising, and enable us to recommend content to individual users based on their profile and activities on the website.
These cookies may be set by us or by third party providers whose services we have added to our websites.
These cookies are non-essential to the functionality of the site and may contain information that enables us or our third party providers to identify you and build a profile of your interests. Without these cookies, you will not be able to have a customized or personalized experience within our website.
Cookies Details‎
Advertising Cookies and Social Media Cookies
Advertising Cookies and Social Media Cookies
Advertising (or Targeting) cookies are third party cookies that may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant ads on other sites.
Social Media Cookies are cookies set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your activities across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit.
These cookies and the data collected by the third parties may be combined with data from other users or data about your activity on other sites. While the data collected on our site is aggregate or non-personal, the data may be used by such third parties to link you on other platforms or otherwise identify you.
If you do not allow these cookies, you may experience less targeted advertising.
Cookies Details‎
Back Button
Cookie List
Search Icon
Filter Icon
Clear
checkbox labellabel
ApplyCancel
ConsentLeg.Interest
checkbox labellabel
checkbox labellabel
checkbox labellabel
View Cookies
Name
cookie name
Save Settings
Download